We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M Turnover 28.57%
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+2.33%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$95.2M
AUM Growth
+$3.46M
Cap. Flow
+$2.54M
Cap. Flow %
2.66%
Top 10 Hldgs %
72.22%
Holding
42
New
7
Increased
9
Reduced
5
Closed
12
Avg Time Held Equity + Options
0.6 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.5 years
Avg Time Held Equity only
0.8 years
Top 10 Avg Time Held Equity only
0.8 years
Top 20 Avg Time Held Equity only
0.7 years

Top Buys

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$7.44M
2
QLTI icon
QLT Inc
QLTI
+$4.59M
3
SEEL icon
Seelos Therapeutics, Inc. Common Stock
SEEL
+$1.91M
4
ABBV icon
AbbVie
ABBV
+$1.63M
5
AORT icon
Artivion
AORT
+$1.58M

Top Sells

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$6.23M
2
LGND icon
Ligand Pharmaceuticals
LGND
+$3.86M
3
TWM icon
ProShares UltraShort Russell2000
TWM
+$3.51M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$964K
5
DGX icon
Quest Diagnostics
DGX
+$812K

Sector Composition

Rank Sector Weight
1 Healthcare 66.02%
2 Miscellaneous 33.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
AMRI
1
DELISTED
Albany Molecular Research Inc
AMRI
$11.5M 12.05%
567,400
+25,000
+5% +$482K
2014 Q1
5 quarters
QLTI icon
2
DELISTED
QLT Inc
QLTI
$8.7M 9.14%
2,107,200
+1,195,000
+131% +$4.59M
2014 Q4
2 quarters
BIS icon
3
CALL
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
$8.62M 9.05%
37,500
+34,375
+1,100% +$8.53M
2015 Q1
1 quarter
MNKD icon
4
PUT
MannKind Corp
MNKD
$977M
$8.36M 8.78%
294,000
+194,000
+194% +$4.96M
2015 Q1
1 quarter
ANIP icon
5
ANI Pharmaceuticals
ANIP
$1.66B
$7.76M 8.15%
+125,000
New +$7.44M
2015 Q2
0 quarters
AZN icon
6
AstraZeneca
AZN
$257B
$6.37M 6.69%
100,000
– –
2013 Q2
8 quarters
PFE icon
7
Pfizer
PFE
$169B
$5.03M 5.28%
158,100
– –
2014 Q1
5 quarters
DGX icon
8
Quest Diagnostics
DGX
$25.9B
$4.8M 5.04%
66,208
-11,000
-14% -$812K
2013 Q2
8 quarters
AORT icon
9
Artivion
AORT
$1.06B
$4.17M 4.38%
370,000
+149,000
+67% +$1.58M
2014 Q3
3 quarters
TWM icon
10
CALL
ProShares UltraShort Russell2000
TWM
$70.3M
$3.48M 3.65%
+5,000
New +$3.51M
2015 Q2
0 quarters
TWM icon
11
ProShares UltraShort Russell2000
TWM
$70.3M
$3.48M 3.65%
5,000
-5,000
-50% -$3.51M
2014 Q1
5 quarters
AGN
12
DELISTED
Allergan plc
AGN
$3.04M 3.19%
10,000
– –
2015 Q1
1 quarter
BIS icon
13
ProShares UltraShort NASDAQ Biotechnology
BIS
$2M
$2.87M 3.02%
12,500
– –
2015 Q1
1 quarter
ADYX
14
DELISTED
Adynxx Inc
ADYX
$2.22M 2.33%
7,017
+3,750
+115% +$1.11M
2015 Q1
1 quarter
VIRX icon
15
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.11M 2.21%
3,333
+2,381
+250% +$1.27M
2015 Q1
1 quarter
ABBV icon
16
AbbVie
ABBV
$504B
$1.68M 1.76%
+25,000
New +$1.63M
2015 Q2
0 quarters
AEGR
17
DELISTED
Aegerion Pharmaceuticals
AEGR
$1.52M 1.59%
80,000
+55,000
+220% +$1.19M
2015 Q1
1 quarter
VIXY icon
18
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$241M
$1.34M 1.41%
+63
New +$1.36M
2015 Q2
0 quarters
SEEL icon
19
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
$1.11M 1.17%
+1
New +$1.91M
2015 Q1
1 quarter
AMRN icon
20
CALL
Amarin Corp
AMRN
$239M
$984K 1.03%
20,000
+10,000
+100% +$450K
2014 Q4
2 quarters
SRNE
21
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$881K 0.93%
50,000
-75,000
-60% -$964K
2014 Q1
5 quarters
SUPN icon
22
CALL
Supernus Pharmaceuticals
SUPN
$2.21B
$849K 0.89%
+50,000
New +$712K
2015 Q2
0 quarters
FCSC
23
DELISTED
Fibrocell Science Inc.
FCSC
$831K 0.87%
10,518
– –
2014 Q1
5 quarters
ARIA
24
DELISTED
Ariad Pharmaceuticals Inc
ARIA
$827K 0.87%
100,000
-50,000
-33% -$442K
2014 Q2
4 quarters
CYTK icon
25
Cytokinetics
CYTK
$8.61B
$672K 0.71%
100,000
– –
2014 Q4
2 quarters
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q2 2015 Portfolio in Review

As of Q2 2015, Healthcare Value Capital held 42 positions worth $95.2M, up 3.8% from $91.8M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Healthcare Value Capital's Q2 2015 filing shows 7 new, 9 increased, 5 reduced and 12 closed positions. Its largest new stake was ANI Pharmaceuticals: 125,000 shares worth $7.76M. The largest sale was Teva Pharmaceutical Industries Limited, an estimated $6.23M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 61% a quarter earlier, followed by Miscellaneous.

  • Healthcare Value Capital's largest Q2 2015 buy was ANI Pharmaceuticals: 125,000 shares worth $7.76M.
  • Healthcare Value Capital added most to QLT Inc in Q2 2015, an estimated $4.59M increase.
  • Healthcare Value Capital's biggest Q2 2015 reduction was ProShares UltraShort Russell2000, cutting an estimated $3.51M.
  • Healthcare Value Capital fully exited Teva Pharmaceutical Industries Limited in Q2 2015, selling an estimated $6.23M.
  • Healthcare Value Capital's ten largest holdings make up 72% of its $95.2M portfolio in Q2 2015.
  • Healthcare Value Capital opened 7 new positions and closed 12 in Q2 2015.
  • Healthcare Value Capital's portfolio value rose 3.8% quarter-over-quarter to $95.2M.

Based on Healthcare Value Capital's 13F filing for Q2 2015, filed 14 Aug 2015.